January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

January 8, 2018 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Basel, 08 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s medical... Read more

January 4, 2018 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools M&A, Partnerships

Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver... Read more

January 2, 2018 M&A, Partnerships

BIO-TECHNE ACQUIRES ATLANTA BIOLOGICALS INC.

MINNEAPOLIS, Jan. 2, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc.. The transaction is financed through available cash on hand. Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne, commented, “Atlanta Biologicals is a great... Read more

December 29, 2017 M&A, Partnerships

Thermo Fisher Scientific Completes Acquisition of Phenom-World

WALTHAM, Mass., Dec. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has completed the acquisition of Phenom-World, a leader in desktop scanning electron microscopy (SEM) solutions. Thermo Fisher will integrate the business into Thermo Fisher’s Analytical Instruments segment. Terms of the transaction were not disclosed. Based in... Read more

December 29, 2017 M&A, Partnerships

BD Completes Bard Acquisition, Creating New Global Health Care Leader

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. The combined company is uniquely positioned to... Read more

December 29, 2017 M&A, Partnerships PR/Corporate

BD Announces Expiration and Final Results of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the expiration and final results of its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C.... Read more

December 28, 2017 M&A, Partnerships PR/Corporate

BD Announces Extension of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes

FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with its previously announced offers to exchange (the “Exchange Offers”) any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026 (collectively, the “Bard Notes”) issued by C. R. Bard, Inc. (“Bard”) for new... Read more

December 28, 2017 M&A, Partnerships

BD Statement On MOFCOM Clearance Of Bard Acquisition

FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the Ministry of Commerce of the People’s Republic of China (MOFCOM) for BD to acquire C. R. Bard (NYSE: BCR), contingent on BD divesting its soft... Read more

December 22, 2017 M&A, Partnerships Microscopy

BD Statement On FTC Clearance Of Bard Acquisition

FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD’s soft tissue core needle biopsy product... Read more